Easy to blame the CEO - they can't answer back. In the end, BIT pays the CRO and can push them for results - it is not the other way around.
Before that, BIT blamed COVID long after lock downs had ended.
Maybe the fault lies in picking a CRO without doing due diligence on how good the CRO is. Maybe they were just going for the cheapest and did not find out that the analysis was being undertaken in a school science lab. Who knows.
What is a known factor is that the onus is on BIT to inform shareholders accurately and transparently where everything is up to.
They announced the end of the physical trial in August last year - it could be August this year before shareholders get the final report details.
BIT Price at posting:
5.6¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
